- 6/25/13: Myriad Genetics (MYGN) and TESARO (TSRO) enter into companion diagnostic agreement (MYGN) 26.24 +0.49 : Co announced that it has signed an agreement with TESARO (TSRO) to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in two separate Phase III clinical studies with niraparib. Niraparib is a novel, orally active poly (ADP-ribose) polymerase, or PARP, inhibitor. TESARO plans to conduct two Phase III clinical studies with niraparib. A Phase III study in platinum sensitive, high grade serous ovarian cancer patients is planned to begin enrolling in mid-2013, and a Phase III study in metastatic breast cancer patients who have germline BRCA mutations is planned to initiate in 2H 2013. Under the terms of the agreement, Myriad BRACAnalysis test will be used as a companion diagnostic to identify patients in TESARO's pivotal clinical trials for niraparib.
Tuesday, June 25, 2013
TESARO (TSRO) - news
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment